On this page
Chromosome 9
Home of the 9p21 cardiovascular/cancer locus and the ABL1 partner in the Philadelphia translocation.
Schematic of chromosome 9 showing the short (p) and long (q) arms. Arm ratio per GRCh38 - banding schematic.
Available at Jeen Health
Clinical tests that include this
Overview
Chromosome 9 is a submetacentric chromosome measuring 138.4 megabases in length and containing approximately 785 protein-coding genes. The centromere sits off-centre, creating a shorter p arm and a longer q arm, a configuration shared by many human autosomes. Unlike chromosomes 13, 18, and 21, whole-chromosome gains or losses of chromosome 9 are not compatible with survival, so it is not associated with common trisomy syndromes. Nevertheless, chromosome 9 is clinically significant for its gene content and for specific structural rearrangements that underpin inherited cancer syndromes and somatic malignancies.
The most widely studied region on chromosome 9 is the 9p21.3 locus, which genome-wide association studies have repeatedly linked to coronary artery disease, type 2 diabetes, and several cancers. This band contains CDKN2A, a tumour-suppressor gene encoding two key cell-cycle regulators, and nearby non-coding variants that influence cardiovascular risk independently of traditional lipid or blood-pressure pathways. Further down the long arm, 9q34 carries ABL1, the tyrosine-kinase gene involved in the Philadelphia chromosome translocation seen in chronic myeloid leukaemia. The chromosome also hosts the ABO blood-group locus at 9q34.13, determining whether an individual expresses A, B, AB, or O antigens on red cells.
Because chromosome 9 is not among the smaller chromosomes and does not participate in common trisomy syndromes compatible with live birth, whole-chromosome gains or losses are rarely encountered in postnatal life. The primary clinical encounters involve microdeletion syndromes at 9p, gene-specific pathogenic variants in tumour suppressors or structural proteins, and somatic rearrangements in haematological malignancies.
Structure
Like all human chromosomes, chromosome 9 consists of a single, continuous DNA double helix wound around histone proteins to form nucleosomes, which in turn coil into chromatin fibres. During cell division the chromatin condenses further, producing the compact, rod-shaped structure visible under a microscope at metaphase. The short arm (p arm) extends from the centromere toward one telomere, whilst the long arm (q arm) reaches toward the opposite end. Because the centromere lies closer to one end than the other, chromosome 9 is classified as submetacentric, a common architecture among human autosomes.
Chromosome 9 is not acrocentric, so it does not carry the clusters of ribosomal-RNA genes found on the short arms of chromosomes 13, 14, 15, 21, and 22. Instead, both the p and q arms contain a mixture of gene-rich and gene-poor segments, interspersed with repetitive elements and regulatory sequences. The pericentromeric region is densely packed with repetitive DNA that helps ensure accurate chromosome segregation, whilst the telomeres at each end protect the chromosome from degradation and end-to-end fusion. Throughout the cell cycle, chromosome 9 is replicated with high fidelity by DNA polymerases, and any damage is detected and repaired by multi-protein surveillance systems, several of which are encoded elsewhere in the genome but act on all chromosomes equally.
Video: What is a karyotype?
Notable regions
The 9p21.3 band has attracted intense scrutiny since genome-wide association studies in the mid-2000s identified common variants in this region that confer significant population-level risk for coronary artery disease, myocardial infarction, and several cancers. The locus contains CDKN2A, which encodes both p16INK4a (via exons 1α, 2, and 3) and p14ARF (in humans, via exon 1β spliced to exons 2 and 3), two tumour suppressors that regulate the cell cycle by inhibiting cyclin-dependent kinases and stabilising p53, respectively. Germline deletions or point mutations in CDKN2A markedly raise the risk of melanoma and pancreatic adenocarcinoma, whilst the common non-coding variants nearby are thought to influence the expression of CDKN2A and neighbouring genes in vascular smooth muscle and endothelial cells, thereby modulating atherosclerotic plaque formation.
Moving to the long arm, 9q34.1 is home to ABL1, which encodes a non-receptor tyrosine kinase involved in cell growth, differentiation, and survival. ABL1 itself does not typically harbour germline pathogenic variants that cause Mendelian disease, but it is the partner in the t(9;22)(q34.1;q11.2) reciprocal translocation that produces the Philadelphia chromosome, a hallmark of chronic myeloid leukaemia and a subset of acute lymphoblastic leukaemias. The translocation fuses part of the BCR gene on chromosome 22 to ABL1, creating a chimeric oncoprotein with constitutive kinase activity. Targeted therapy with tyrosine-kinase inhibitors such as imatinib has transformed the prognosis of chronic myeloid leukaemia, making this one of the most successful examples of precision oncology.
Further along at 9q34.13 lies the ABO locus, a trio of alleles (A, B, and O) that determine red-cell surface antigens crucial for safe blood transfusion. The A and B alleles encode glycosyltransferases that add specific sugars to a precursor molecule on the erythrocyte membrane, whilst the O allele carries a frameshift mutation that abolishes enzyme function. Although ABO genotype is not a disease determinant in the traditional sense, it has epidemiological associations with thrombosis risk, gastric cancer susceptibility (linked to Helicobacter pylori binding), and severe outcomes in certain infections, illustrating how a single genetic locus can have pleiotropic effects across diverse physiological systems.
Notable genes
Among the genes on chromosome 9 that feature in the Jeen Health library, TSC1 at 9q34.13 is particularly well characterised. TSC1 encodes hamartin, which partners with tuberin (encoded by TSC2 on chromosome 16) to form a complex that inhibits mTOR signalling, a central pathway controlling cell growth and metabolism. Pathogenic variants in TSC1 cause tuberous sclerosis complex, an autosomal-dominant disorder characterised by benign tumours in the brain, skin, kidneys, heart, and lungs. Individuals with tuberous sclerosis may present with epilepsy (including infantile spasms in West syndrome), intellectual disability, facial angiofibromas, renal angiomyolipomas, and, in a subset of cases, lymphangioleiomyomatosis affecting the lungs. Because mTOR inhibitors can shrink certain TSC-related tumours, understanding the TSC1-TSC2 pathway has direct therapeutic implications.
TGFBR1, located at 9q22.33, encodes one half of the transforming-growth-factor-beta receptor complex. Pathogenic variants in TGFBR1 disrupt signalling pathways that regulate vascular development and maintenance, leading to Loeys-Dietz syndrome, an autosomal-dominant connective-tissue disorder with aortic-root dilatation, arterial tortuosity, skeletal features, and a propensity for early arterial dissection. The phenotypic overlap with Marfan syndrome and vascular Ehlers-Danlos syndrome underscores the importance of molecular diagnosis, particularly given differences in surgical management thresholds and reproductive counselling. Other launch genes on chromosome 9 include SIGMAR1, PIGO, HNRNPK, and FREM1, each associated with rarer phenotypes ranging from neurodevelopmental conditions to disorders of glycosylphosphatidylinositol-anchor biosynthesis.
Chromosomal disorders
Whilst whole-chromosome trisomy or monosomy of chromosome 9 is not compatible with survival to term, partial deletions and duplications do occur and give rise to recognisable clinical patterns. The best-delineated syndrome is 9p deletion syndrome, typically caused by a terminal or interstitial deletion removing part of the short arm. The critical region is thought to include the DMRT1 gene, although multiple genes contribute to the phenotype. Affected individuals may present with developmental delay, intellectual disability, characteristic facial features (including a broad nasal bridge and downslanting palpebral fissures), and, in 46,XY individuals with deletions encompassing DMRT1, partial or complete gonadal dysgenesis leading to ambiguous or female external genitalia. Because the size and breakpoints of 9p deletions vary, the clinical severity is correspondingly variable, and chromosomal microarray is the usual diagnostic modality to define the deletion precisely.
Most 9p deletions arise de novo, meaning they are not inherited from either parent but occur as a random event during the formation of egg or sperm (affecting that conception only), or very rarely as mosaicism in a parent's germline. Recurrence risk for future pregnancies is therefore low in the absence of parental mosaicism or a balanced rearrangement. If a parent carries a balanced translocation involving chromosome 9, however, the risk of unbalanced offspring rises substantially, and preimplantation or prenatal diagnosis may be considered. Ring chromosome 9, in which both telomeres are lost and the chromosome circularises, has also been reported and typically produces a more severe phenotype because of the loss of genetic material from both arms and ring instability during cell division, which can lead to further loss of genetic material in some cells. For any structural abnormality of chromosome 9 detected prenatally or postnatally, referral to NHS clinical genetics is recommended for detailed chromosomal analysis, phenotype-genotype correlation, and tailored family counselling.
Prenatal screening & diagnosis
Non-invasive prenatal testing based on cell-free foetal DNA does not routinely screen for abnormalities of chromosome 9, because whole-chromosome aneuploidies of this autosome are typically not viable. NIPT panels offered through the NHS and private providers focus on trisomies 13, 18, and 21, and sex-chromosome aneuploidies, with optional microdeletion screening that does not currently include 9p deletion syndrome as standard. If a foetal structural anomaly is detected on ultrasound, particularly genital ambiguity, renal malformations, or markers of a syndromic condition, the next step is diagnostic testing via chorionic-villus sampling or amniocentesis followed by karyotyping or chromosomal microarray.
Chromosomal microarray has become the first-line test in many NHS genetics laboratories when a structural chromosome abnormality is suspected, because it detects deletions and duplications across the genome at much higher resolution than conventional G-banded karyotyping. A karyotype may still be performed in parallel to identify balanced translocations or other rearrangements that microarray cannot detect. Parental samples are often requested if a deletion or duplication is found in the fetus, to determine whether the abnormality is de novo or inherited. This information is crucial for recurrence-risk counselling and may influence decisions about further prenatal testing in subsequent pregnancies.
Inheritance & recurrence
The majority of structural abnormalities involving chromosome 9 occur sporadically and are not inherited from a parent. De-novo deletions at 9p, for example, typically arise from errors in meiosis or early mitotic divisions, and the empirical recurrence risk for another chromosomal abnormality is often quoted at around 1% (slightly above the general population risk), accounting for the small possibility of undetected parental mosaicism. If either parent carries a balanced translocation involving chromosome 9, the recurrence risk is considerably higher, potentially 10-25% or more depending on the specific breakpoints and the segregation pattern, and detailed cytogenetic counselling is essential.
For single-gene conditions such as tuberous sclerosis complex caused by pathogenic variants in TSC1, inheritance follows an autosomal-dominant pattern, meaning a single mutated copy is sufficient to cause disease. Many individuals with tuberous sclerosis represent new mutations, but once a variant is identified in a parent, each child has a 50% chance of inheriting it. Penetrance is very high, but expressivity is variable, so clinical severity can differ markedly even within a family. Loeys-Dietz syndrome linked to TGFBR1 variants follows a similar autosomal-dominant pattern. For any family with a diagnosed or suspected chromosomal or single-gene disorder on chromosome 9, NHS clinical genetics services offer risk assessment, carrier testing where appropriate, and discussion of reproductive options including preimplantation genetic testing.
Frequently asked questions
What is the 9p21 locus, and why does it matter for heart disease?
The 9p21.3 region contains common genetic variants that increase the risk of coronary artery disease and heart attacks across diverse populations. Although the exact mechanism is still being studied, research suggests these variants influence how vascular cells respond to injury and inflammation, independent of cholesterol levels or blood pressure. The locus also harbours CDKN2A, a tumour-suppressor gene linked to melanoma and pancreatic cancer risk.
Can chromosome 9 abnormalities be detected before birth?
Whole-chromosome trisomy or monosomy of chromosome 9 is not compatible with survival, so these abnormalities are not included in routine non-invasive prenatal testing. If an ultrasound scan raises concern for a structural problem, diagnostic testing via chorionic-villus sampling or amniocentesis followed by karyotyping or chromosomal microarray can identify deletions or duplications of part of chromosome 9, such as 9p deletion syndrome.
What is the Philadelphia chromosome, and how is it treated?
The Philadelphia chromosome results from a translocation between chromosomes 9 and 22, fusing the BCR gene on chromosome 22 to the ABL1 gene on chromosome 9. This creates a hybrid protein with uncontrolled kinase activity, driving chronic myeloid leukaemia and some cases of acute lymphoblastic leukaemia. Targeted drugs called tyrosine-kinase inhibitors, such as imatinib, block the abnormal protein and have dramatically improved outcomes for people with these cancers.
If my child has a 9p deletion, will my next child have the same condition?
Most 9p deletions occur as new, random events and are not inherited, so the recurrence risk for future pregnancies is low, typically around 1%. However, if either parent carries a balanced rearrangement involving chromosome 9, the risk is higher. A clinical genetics appointment can clarify your family's specific risk through parental chromosome testing and provide options for prenatal or preimplantation diagnosis if desired.
How do genetic changes on chromosome 9 cause tuberous sclerosis?
Tuberous sclerosis complex arises when a pathogenic variant in either TSC1 on chromosome 9 or TSC2 on chromosome 16 disrupts a protein complex that normally restrains cell growth. Loss of this control allows benign tumours to form in the brain, kidneys, heart, skin, and lungs. Because the condition is autosomal dominant, inheriting one altered copy is enough to cause disease, although severity varies widely even among family members with the same variant.
Launch-set genes on chromosome 9
Genes on this chromosome that currently have dedicated pages in the library. This list grows as we publish more.